Eli Lilly and Co., US5324571083

Eli Lilly stock targets oncology growth in 5.9 billion deal

Published on 11/18/2026 at 13:34 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Eli Lilly and Company stock is in focus after a new oncology collaboration with Stipple Bio. The deal expands Lilly's research pipeline.

Oncology deal broadens Lilly pipeline

  • The collaboration gives Lilly exclusive worldwide rights to products emerging from Stipple Bio's platform.
  • Stipple Bio will receive upfront and equity payments plus research, development and commercial milestones.
  • The agreement adds precision-oncology research to Lilly's existing cancer portfolio.
Eli Lilly and Co., US5324571083, Illustration mit AI erstellt.

On November 16, Reuters reported that Eli Lilly and Company signed an oncology research collaboration and licensing agreement with Stipple Bio worth up to 5.9 billion US dollars. The deal gives Lilly access to Stipple's technology for identifying molecules that distinguish cancer cells from healthy tissue.

The agreement covers multiple drug targets and therapeutic approaches. Stipple Bio will receive an undisclosed upfront payment and an equity investment from Lilly, as well as aggregate research, development and commercial milestone payments. The biotech will also be eligible for tiered royalties if therapies from the collaboration reach the market.

The companies did not disclose the upfront payment or the size of Lilly's equity investment. Lilly secured exclusive worldwide rights to develop and commercialize products arising from the collaboration, while Stipple's platform is intended to support more selective cancer treatments with the potential to reduce damage to healthy tissue.

Pipeline expansion beyond obesity drugs

The agreement adds another research channel to Lilly's oncology strategy as the company seeks to broaden its portfolio beyond diabetes and obesity medicines. Lilly's current oncology products include the breast cancer treatment Verzenio and the blood cancer treatment Jaypirca. The company is also developing targeted therapies, antibody-drug conjugates and immuno-oncology medicines.

Stipple Bio is developing precision-oncology therapies from its Cambridge, Massachusetts base. Its lead candidate, STP-100, is expected to enter an early-stage trial in early 2027 in solid tumors including pancreatic cancer. The collaboration therefore remains an early pipeline investment, with commercial returns dependent on research progress, clinical development and regulatory outcomes.

Reuters reported the agreement on November 16 and said Lilly declined to comment beyond the company's announcement. The transaction follows Lilly's separate agreement to acquire Calytrix Bio for up to 1.5 billion US dollars, adding to a recent series of deals aimed at expanding the drugmaker's development pipeline.

Eli Lilly stock traded at 1,283.20 euros on Lang & Schwarz at 13:31 CET on Wednesday, November 18, 0.25 percent below the Xetra close of Tuesday, November 17. The quote was below the prior session's Xetra close as the market assessed the company's broader pipeline and recent transaction activity.

Company facts

Eli Lilly and Company

  • ISIN: US5324571083
  • Ticker: LLY
  • Primary exchange: NYSE
  • Lang & Schwarz quote: 1,283.20 euros at 13:31 CET on November 18, 2026
  • Xetra close: 1,286.40 euros on November 17, 2026

The S&P 500 provides the market context for Eli Lilly's US primary listing.

For more coverage, see More news and analyses on Eli Lilly and Company stock.

Disclaimer...
en | US5324571083 | ELI LILLY AND CO. | boerse | 70530909 | bgmi